Last Updated: August 2026
Published by: Orio Pharma — a specialist oncology medicine supplier serving patients, pharmacies, and distributors worldwide.
Medical Review: Reviewed by Dr. Farhan Hossain, MBBS, MD (Oncology)
Content Basis: This article is based on official prescribing information, product monographs, and regulatory product documentation from DGDA (Directorate General of Drug Administration, Bangladesh).
Sources: medsbd.com, medex.com.bd, medex.com.bd

Key Takeaways
- Hexinor is the Bangladeshi brand of Trihexyphenidyl Hydrochloride, manufactured domestically by Beacon Pharmaceuticals Ltd. and sourced directly for supply within Bangladesh.
- It is approved as an adjunct treatment for all forms of parkinsonism, including postencephalitic, arteriosclerotic, and idiopathic parkinsonism.
- As an anticholinergic agent, Hexinor works alongside other antiparkinsonian therapies rather than as a standalone treatment.
- Hexinor is available as an oral tablet in three strengths — 1 mg, 2 mg, and 5 mg — allowing physicians to tailor therapy to individual patient needs.
- The product falls under the regulatory oversight of Bangladesh’s Directorate General of Drug Administration (DGDA), which governs domestic pharmaceutical manufacturing and distribution.
- Institutional buyers can access Hexinor through direct, verified sourcing relationships with the manufacturer, supporting supply chain traceability and authenticity.
Hexinor: Product Overview
Hexinor is the Bangladeshi brand of Trihexyphenidyl Hydrochloride, an antiparkinsonian agent belonging to the anticholinergic (antimuscarinic) therapeutic class. It is manufactured by Beacon Pharmaceuticals Ltd. (also listed as Beacon Pharmaceuticals PLC) and is sourced directly from Bangladeshi manufacturers for supply to pharmacies, hospitals, and healthcare institutions across the domestic market.
Hexinor is formulated as an oral tablet and is available in three strengths — 1 mg, 2 mg, and 5 mg — allowing prescribers flexibility in tailoring therapy within the approved indication. As a domestically produced pharmaceutical, Hexinor offers institutional buyers a locally manufactured alternative that aligns with Bangladesh’s pharmaceutical procurement framework, avoiding the complexities associated with imported anticholinergic agents. Buyers searching for related product listings such as hexinor 2 mg or hexinor2 will find that these refer to the same core formulation, differentiated only by tablet strength. This overview establishes the foundation for procurement teams evaluating Hexinor as a reliable, locally sourced option for parkinsonism management support within their formularies.
Note: This article is intended for pharmacy, hospital, and institutional procurement audiences and does not constitute clinical guidance. Prescribing decisions for individual patients rest solely with qualified, treating physicians in accordance with official prescribing information.
Approved Indication and Clinical Use
Hexinor is approved as an adjunct treatment for all forms of parkinsonism, including postencephalitic, arteriosclerotic, and idiopathic parkinsonism.
The adjunct role of Trihexyphenidyl Hydrochloride is significant in clinical practice, as parkinsonism management frequently requires a multi-drug approach to address the range of motor and non-motor symptoms associated with the condition. Hexinor’s classification covers all three recognized etiologies of parkinsonism recognized in the approved indication — whether the condition arises following encephalitis, is linked to cerebrovascular changes, or presents idiopathically. Healthcare providers and institutional buyers can rely on this indication scope when evaluating Hexinor for inclusion in treatment protocols for patients requiring anticholinergic support as part of a broader parkinsonism management plan. Procurement decisions should always be guided by the treating physician’s clinical judgment and the official prescribing information accompanying each batch supplied.
Clinical pharmacology teams and hospital formulary committees reviewing Hexinor for inclusion should cross-reference this indication scope against internal treatment protocols and the most current package insert supplied with each shipment, as labeling can be periodically updated in line with DGDA requirements.
Mechanism of Action
Trihexyphenidyl Hydrochloride functions as an anticholinergic agent, and its role in parkinsonism management is as an adjunct to other therapeutic interventions. By acting on cholinergic pathways, Trihexyphenidyl helps address the neurotransmitter imbalance that contributes to the motor symptoms characteristic of parkinsonism.
This mechanism underlies its classification within the antiparkinsonian agent category and supports its use across postencephalitic, arteriosclerotic, and idiopathic forms of the condition. Institutional buyers and healthcare providers should refer to the official prescribing information for complete pharmacological details when incorporating Hexinor into clinical protocols.
Because anticholinergic agents can interact with a patient’s broader medication regimen, hospital pharmacists and clinical staff are best positioned to assess appropriateness on a case-by-case basis, drawing on the full prescribing information rather than summary content such as this overview.
Available Strengths and Formulations
Hexinor is supplied in three oral tablet strengths: 1 mg, 2 mg, and 5 mg. This range allows prescribing physicians to select an appropriate strength based on individual patient needs and treatment goals within the adjunct parkinsonism indication. Some procurement listings may reference hexinor 2 mg specifically, while broader catalog searches may include terms like hexinor syrup — however, the officially supplied formulation is the oral tablet across the three listed strengths.
Specific dosing regimens, including strength selection and administration frequency, must be determined exclusively by the treating physician in accordance with the official prescribing information. Pharmacies and healthcare providers sourcing Hexinor should ensure that dispensing practices align strictly with physician instructions and the product’s approved labeling. No dosing amount should be inferred from availability data alone; strength options exist solely to support individualized, physician-directed care.
Procurement teams are advised to confirm current strength availability and batch-specific labeling directly with the manufacturer at the time of order, as formulation listings may be updated over time.

Regulatory Status in Bangladesh
Pharmaceutical products distributed in Bangladesh, including Hexinor, fall under the regulatory oversight of the Directorate General of Drug Administration (DGDA, dgda.gov.bd), the national authority responsible for licensing, monitoring, and regulating drug manufacturing and distribution within the country. Hexinor is manufactured domestically by Beacon Pharmaceuticals Ltd., operating within this established Bangladeshi regulatory framework.
As a locally manufactured product, Hexinor’s production and distribution are subject to the standard compliance requirements set forth by DGDA for pharmaceutical manufacturers operating in Bangladesh. Institutional buyers and healthcare providers are encouraged to verify current regulatory documentation directly with DGDA or through the manufacturer when required for procurement or tender purposes. This article does not assert specific certifications beyond what is confirmed through official channels, ensuring that all regulatory representations remain accurate and verifiable for B2B decision-making.
We recommend that institutional buyers retain copies of relevant DGDA registration and batch documentation as part of their internal compliance and audit trail when adding Hexinor to procurement records.
Why Choose Us as Your Hexinor Supplier in Bangladesh
Pharmacies, hospitals, and healthcare providers across Bangladesh require sourcing partners who can guarantee authenticity and consistency in pharmaceutical supply. As a domestic B2B supplier, we position ourselves as a verified sourcing partner for Hexinor, working directly with the manufacturer to ensure that every unit supplied traces back to legitimate domestic manufacturing.
Our approach emphasizes direct manufacturer relationships rather than intermediary layers that can compromise product traceability. This direct sourcing model allows us to maintain consistent availability of all three Hexinor tablet strengths — 1 mg, 2 mg, and 5 mg — while supporting institutional buyers who require dependable supply chains for adjunct parkinsonism therapies.
For pharmacies and healthcare providers evaluating suppliers, reliability extends beyond product availability to encompass responsive communication, accurate order fulfillment, and adherence to Bangladesh’s regulatory expectations. We understand the operational demands faced by procurement teams managing formularies that include anticholinergic agents like Trihexyphenidyl Hydrochloride, and we structure our supply relationships to minimize disruption and support continuity of patient care. Choosing a supplier with demonstrated commitment to domestic sourcing integrity helps healthcare institutions reduce risk and maintain confidence in the pharmaceutical products they dispense.
Verified Sourcing and Distribution Assurance
Authenticity is a foundational concern for any institution procuring pharmaceutical products. To address this, our supply chain for Hexinor is built on a verified sourcing process that connects directly to Beacon Pharmaceuticals Ltd., the domestic manufacturer of this Trihexyphenidyl Hydrochloride formulation.
This direct-sourcing approach reduces the risk of counterfeit or diverted products entering the supply chain, a critical consideration for pharmacies and healthcare providers responsible for patient safety. By maintaining a documented, traceable relationship with the manufacturer, we reinforce trust and legitimacy at every stage of distribution — from initial order confirmation through final delivery. Institutional buyers can rely on this verification framework when sourcing Hexinor 1 mg, 2 mg, or 5 mg tablets for their formularies, knowing that supply integrity has been prioritized throughout the process.
We encourage procurement teams to request batch documentation and manufacturer verification materials at the time of purchase, reinforcing accountability at each step of the ordering process.
About Us
We are a Bangladeshi B2B pharmaceutical supplier dedicated to connecting pharmacies and healthcare providers with authentic, domestically manufactured medications. Our focus on direct sourcing relationships with established manufacturers enables us to support the pharmaceutical supply needs of institutions across Bangladesh’s healthcare sector. We serve hospitals, retail pharmacies, and clinical procurement teams seeking dependable access to therapies such as Hexinor for adjunct parkinsonism management. Our team works to stay current with DGDA regulatory updates and manufacturer communications so that the institutions we serve can procure with confidence. Contact us for availability and pricing.
Side Effects and Safety Profile
The adverse reactions below are transcribed from the Trihexyphenidyl Hydrochloride Tablets USP, DailyMed (FDA label), Adverse Reactions. Commonly reported reactions include dryness of the mouth, blurred vision, dizziness, mild nausea, nervousness.
Reactions requiring clinical attention include confusion; memory impairment; constipation; drowsiness; urinary hesitancy or retention; tachycardia; increased intraocular pressure; paralytic ileus; delusions; hallucinations. This summary is not a complete safety profile: prescribers and dispensing pharmacists should consult the full approved prescribing information for Trihexyphenidyl Hydrochloride before initiating or dispensing therapy, and patients should consult their doctor or pharmacist about any unexpected symptom.
Safety data source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b7e4200c-feff-4537-aad1-cf9989fd8c14
Frequently Asked Questions
What is Hexinor used for?
Hexinor is used as an adjunct treatment for all forms of parkinsonism, including postencephalitic, arteriosclerotic, and idiopathic parkinsonism, and is typically combined with other antiparkinsonian agents as directed by a physician.
What is Hexinor 1mg used for?
Hexinor 1 mg is one of three available tablet strengths of the same Trihexyphenidyl Hydrochloride formulation, used for the same adjunct parkinsonism indication as the 2 mg and 5 mg strengths.
What are the side effects of Hexinor?
The article does not detail specific side effects of Hexinor and instead directs pharmacies and healthcare providers to consult the official prescribing information accompanying each supplied batch.
Can Hexinor be used alone to treat Parkinson’s disease?
No, Hexinor is classified as an adjunct anticholinergic agent, meaning it is intended to complement other antiparkinsonian therapies rather than serve as a standalone treatment.
Who manufactures Hexinor and is it regulated in Bangladesh?
Hexinor is manufactured domestically by Beacon Pharmaceuticals Ltd. and falls under the regulatory oversight of Bangladesh’s Directorate General of Drug Administration (DGDA), which licenses and monitors pharmaceutical manufacturing and distribution nationwide.
How can pharmacies and hospitals source Hexinor reliably?
Pharmacies and hospitals can source Hexinor through direct sourcing relationships with the manufacturer, which help ensure product traceability and reduce the risk of counterfeit or diverted supply. This direct-sourcing model supports consistent availability across all three tablet strengths for institutional formularies.
Related Oncology Medications
Access This Medicine Through Orio Pharma
We are a specialist oncology medicine supplier delivering to patients, pharmacies, hospitals, and distributors worldwide. Contact us for availability and sourcing support.
We do not publish prices online. All pricing is provided directly by our specialist supply team on request.
Medical Information Notice: This content is for informational purposes only and is based on official pharmaceutical product documentation. It does not constitute medical advice. Patients should consult their doctor or pharmacist before taking any medication.
Regulatory Disclaimer: Sourcing and distribution are subject to regional import regulations, quotas, and verified medical prescriptions where applicable. Pricing and availability are subject to change without notice.
Content Currency: This article was last reviewed and updated in August 2026. Regulatory approval statuses and product availability are subject to change; readers are advised to consult official regulatory databases for the most current information.